Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by LPL Financial LLC

LPL Financial LLC reduced its position in Revance Therapeutics, Inc. (NASDAQ:RVNC) by 68.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,375 shares of the biopharmaceutical company’s stock after selling 29,530 shares during the quarter. LPL Financial LLC’s holdings in Revance Therapeutics were worth $41,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Magnetar Financial LLC boosted its stake in shares of Revance Therapeutics by 2.2% in the fourth quarter. Magnetar Financial LLC now owns 2,556,345 shares of the biopharmaceutical company’s stock valued at $7,771,000 after purchasing an additional 56,174 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Revance Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 797,299 shares of the biopharmaceutical company’s stock worth $2,424,000 after buying an additional 6,462 shares in the last quarter. FNY Investment Advisers LLC boosted its position in Revance Therapeutics by 160.4% in the 4th quarter. FNY Investment Advisers LLC now owns 477,823 shares of the biopharmaceutical company’s stock valued at $1,452,000 after buying an additional 294,323 shares during the period. Candriam S.C.A. acquired a new position in shares of Revance Therapeutics in the fourth quarter worth $909,000. Finally, New York Life Investment Management LLC increased its position in shares of Revance Therapeutics by 114.9% during the fourth quarter. New York Life Investment Management LLC now owns 295,670 shares of the biopharmaceutical company’s stock worth $899,000 after acquiring an additional 158,076 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. StockNews.com initiated coverage on Revance Therapeutics in a report on Sunday, April 27th. They issued a “hold” rating for the company. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Nine analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Stock Performance

NASDAQ:RVNC opened at $3.65 on Friday. Revance Therapeutics, Inc. has a 1 year low of $2.30 and a 1 year high of $6.65. The stock has a market cap of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90. The stock has a 50-day simple moving average of $3.65 and a 200-day simple moving average of $3.82.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.